Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

weeks of treatment with ISIS 301012.

The most common drug-related adverse events were painless mild to moderate injection site reactions. There was one possibly drug-related serious adverse event reported for the study: a patient in the 400 mg/dL cohort experienced fever more than 12 hours after receiving the first dose and subsequently dropped out of the study. This patient was not included in the per protocol analysis. In this high dose cohort, one patient had consecutive measurements of liver transaminases (ALT) above three times the upper limit of normal (3xULN); the maximal ALT observed in the study was 211 IU/L. Importantly, no patients evidenced liver chemistries that would suggest risk of liver injury (extremely high ALT or ALT elevations together with elevations in bilirubin greater than 2xULN). Patients in this study remain in follow-up.

According to John J.P. Kastelein, M.D., Ph.D., Chairman, Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands, lead investigator in the study, "ISIS 301012 continues to show exceptional promise as a new lipid-lowering agent. This study demonstrates that as an add-on therapy in patients on statins whose LDL-C levels are not adequately controlled, ISIS 301012 effectively enables patients to achieve target levels of LDL-C. This is an important clinical effect which, together its tolerability and lack of drug interactions, make ISIS 301012 an exciting drug for potential use in combination with other lipid-lowering therapies in the patients unable to derive sufficient benefit from available agents."

Mark Wedel, M.D., J.D., Isis' Chief Medical Officer, added, "ISIS 301012 is highly active and well tolerated in combination with statins, both in the routine high cholesterol population represented in this study, as well as in homozygous familial hypercholesterolemic patients on maximal concurrent lipid-lowering therapies. ISIS 301012 continues to perform to our highest ex
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/22/2015)... 22, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... systems ("EPS"), today announced that its CGuard TM Embolic ... investigator Prof. Piotr Musialek , at the EuroPCR ... France . PARADIGM, an investigator-initiated P ... A roti D revascularization I n symptomatic and ...
(Date:5/22/2015)... 22, 2015 Today, Rhodes Pharmaceuticals L.P. announced ... stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder ... 2015. The announcement comes just ... the U.S. Food and Drug Administration (FDA). ... of methylphenidate capsule with an onset of effect ...
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... WASHINGTON, Aug. 10, 2011 In a just-released National ... Treatment http://www.nmqf.org/IB3SpecialtyTiersFinal.pdf ), Gary Puckrein ... has become popular among insurers (public and private) as ... requiring beneficiaries to pay more for certain high-cost prescription ...
... and ST. AUGUSTINE, Fla., Aug. 10, 2011 ... hospitals, has selected the Sunrise Enterprise ™ suite ... (NASDAQ: MDRX).  In addition to implementing Sunrise within the ... Electronic Health Record (EHR) and practice management solution ...
Cached Medicine Technology:Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 3Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 4Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 5Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 6
(Date:5/25/2015)... A recent report for Mass Live ... died as a direct result of an opiate overdose in ... rise in overdose deaths attributed to prescription opiate medications, and ... care about geography. This issue doesn’t care about race. This ... class.” As the state of Mass. reels from the effects ...
(Date:5/25/2015)... After the sensational buzz surrounding their ... wellness company Trivedi Master Wellness™ agrees to ... series titled, “Consciousness is Power.” Presently, the Live-Streaming event ... at the routinely allotted time from 10:00pm PST/1:00pm EST ... made available to the public and accessible on the ...
(Date:5/24/2015)... New York, NY (PRWEB) May 24, 2015 ... begins on Sunday, May 24th in San Diego at Petco ... tour throughout North America. On May 20th, they had ... Theatre. At their preview show in Los Angeles, this ... its entirety; they also played fan favorites such as "Jumping ...
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... 24, 2015 ... - The students were selected ... the fourth annual A Day of ... Geneva National in Lake Geneva. , ... High School,         Jonathan Alfonso,         Bridget Keefe, ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... initiated by World Health,Organization's (WHO) authority to ... unofficial,sources, soon after any outbreak of infectious,diseases ... a crucial decision it was decided that ... on-the-spot,investigations to determine the severity of an,outbreak ...
... on its border with hard-hit China. ,The first confirmed case ... the Amur river, which forms the frontier with China, came ... his country could contain the disease.,Hu told students in Moscow, ... introduced strict measures to stop the spread of the deadly ...
... may benefit non-anemic women between ages 18 and 55 with ... with low ferritin, a protein that stores iron and is ... of Lausanne in Switzerland gave 136 women either 80 milligrams ... The study shows the level of fatigue after one month ...
... The global health community has taken a key ... of infectious diseases and other threats to international ... underlines the World Health Organization’s (WHO) authority to ... unofficial sources, and, when necessary to determine the ...
... the illness have been told to quarantine themselves at ... chief medical officer of health. Precautions taken at ... control dozens of possible new cases. Health officials ... city back on its list of SARS - affected ...
... may have a potential role in treating Alzheimer's. Lithium ... of both the proteins found in Alzheimer's patients. Identification ... other drugs that disrupt the production of both proteins., ... not disrupt the processing of another protein called notch, ...
Cached Medicine News:Health News:WHO Says Toronto Going Back on SARS-Affected List 2Health News:Lithium May help in Alzheimer's Disease 2
The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
Yellow flames radiate out from the center of eye, held in check by the fire-engine red perimeter....
Medicine Products: